^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy of checkpoint inhibition in advanced acral melanoma
Published date:
05/19/2021
Excerpt:
Nighty-five AM patients received at least one dose of anti-PD1 monotherapy...ORR was 28% (complete response 11%; partial response 18%). Median PFS and OS in patients with first-line treatment were 5.5 months (95% CI 3.5-8.4) and 14 months (95% CI 9.3-25.0)....elevated LDH levels, liver metastasis and brain metastasis were significantly associated with lower OS.
DOI:
10.1200/JCO.2021.39.15_suppl.e21527
